Dr Reddys Laboratories (RDY) Depreciation & Amortization (CF) (2009 - 2026)

Dr Reddys Laboratories has reported Depreciation & Amortization (CF) for 18 years, with the latest figure at $56.7 million in Q2 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 1.91% year-over-year to $56.7 million in Q2 2026; TTM through Jun 2026 was $10.9 billion, a 5053.63% increase from a year earlier, with the FY2026 full-year figure at $220.0 million, up 10.0% from the prior year.
• Depreciation & Amortization (CF) was $56.7 million for Q2 2026 at Dr Reddys Laboratories, down from $5.6 billion in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $5.6 billion in Q1 2026, with the low at $38.4 million in Q1 2023.
• Average Depreciation & Amortization (CF) over 5 years is $640.4 million, with a median of $45.8 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: Depreciation & Amortization (CF) dropped 9.49% in 2022, then jumped 10509.63% in 2026.
• Over 5 years, Depreciation & Amortization (CF) stood at $39.8 million in 2022, then advanced by 12.59% to $44.9 million in 2023, then increased by 24.46% to $55.8 million in 2024, then jumped by 9231.71% to $5.2 billion in 2025, then slumped by 98.91% to $56.7 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $56.7 million (Q2 2026), $5.6 billion (Q1 2026), and $5.2 billion (Q4 2025), per Business Quant data.